Literature DB >> 13129839

Bupropion-induced somnambulism.

Yasser Khazaal1, Sonia Krenz, Daniele Fabio Zullino.   

Abstract

Whereas there are some case reports of bupropion-induced vivid dreaming and nightmares, until now it has not been associated with somnambulism. A case is reported of a patient treated with bupropion as a smoking cessation medication, who developed somnambulism during nicotine withdrawal. Furthermore, the sleepwalking episodes were associated with eating behaviour. Amnesia was reported for all episodes. As, on one hand,bupropion is a noradrenergic and dopaminergic drug and nicotine withdrawal, on the other hand, is associated with alterations in monoaminergic functions, an interaction at the level of these neurotransmitters is suggested as the underlying mechanism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13129839     DOI: 10.1080/13556210310001602284

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  6 in total

1.  Sleepwalking.

Authors:  Valérie Cochen De Cock
Journal:  Curr Treat Options Neurol       Date:  2016-02       Impact factor: 3.598

2.  Sexual behaviour in sleep: an internet survey.

Authors:  Nikola N Trajanovic; Michael Mangan; Colin M Shapiro
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2007-10-11       Impact factor: 4.328

3.  Somnambulism During Monotherapy With Mixed Amphetamine Salts.

Authors:  Subhash Pinnaka; Khrisan Gosai; Cezary Czekierdowski; Pamela P Siller; Kyle A B Lapidus
Journal:  J Clin Psychopharmacol       Date:  2016-04       Impact factor: 3.153

Review 4.  Parasomnias: an updated review.

Authors:  Michael J Howell
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

5.  Parasomnias and antidepressant therapy: a review of the literature.

Authors:  Lara Kierlin; Michael R Littner
Journal:  Front Psychiatry       Date:  2011-12-12       Impact factor: 4.157

6.  Active Reward Processing during Human Sleep: Insights from Sleep-Related Eating Disorder.

Authors:  Lampros Perogamvros; Patrick Baud; Roland Hasler; Claude Robert Cloninger; Sophie Schwartz; Stephen Perrig
Journal:  Front Neurol       Date:  2012-11-27       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.